If Trikafta Isn’t Good Enough for ICER, What Drug Is?
TIMMERMAN REPORT - MAY 2020
Jessica Sagers, PhD
The Institute for Clinical and Economic Review (ICER) recently concluded that Trikafta, a new, groundbreaking cystic fibrosis drug developed by Vertex, isn't worth its price. But ICER's cost-effectiveness analyses routinely refuse to include variables that do not suit the organization's political agenda. Insisting on modeling a drug's launch price as its price forever without taking into account the fact that it will go generic is distinctly disingenuous.
VIEW PDF